Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

520
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
520
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

908
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
908

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data-driven RNA phenotyping captures genetically regulated dimensions of the transcriptome.

American journal of human genetics·2026
Same author

Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

Nature communications·2026
Same author

Leveraging tumor dynamics to discover mutations influencing progression and treatment response for precision oncology.

Genome medicine·2026
Same author

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients.

JAMA network open·2026
Same author

Somatic mutations reveal hyperactive Notch signaling in prurigo nodularis.

JCI insight·2026
Same author

Functional synergistic effects of graphene nanoribbons and surfactant stabilizers on inhibition of growth of biofilm-forming and biofilm non-forming bacteria.

Environmental science and pollution research international·2026
Same journal

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA oncology·2026
Same journal

Cardiac Risk After Heart-Sparing Breast Radiotherapy.

JAMA oncology·2026
Same journal

When Not to Push the Boulder.

JAMA oncology·2026
Same journal

Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.

JAMA oncology·2026
Same journal

Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer.

JAMA oncology·2026
Same journal

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2025

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

16.7K

Identification of Immune Checkpoint Inhibitor-Induced Diabetes.

Karina N Ruiz-Esteves1, Kaitlyn R Shank2, Aaron J Deutsch3,4

  • 1Department of Medicine, Massachusetts General Hospital, Boston, MA and Harvard Medical School, Boston.

JAMA Oncology
|August 29, 2024
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitor (ICI) therapy can cause diabetes, a serious immune-related adverse event (irAE). Preexisting type 2 diabetes and combination ICI treatment are risk factors, with genetic predisposition also playing a role.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

254
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K

Related Experiment Videos

Last Updated: Jun 14, 2025

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

16.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

254
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K

Area of Science:

  • Oncology
  • Immunology
  • Endocrinology

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can cause immune-related adverse events (irAEs).
  • Life-threatening irAEs may necessitate discontinuing ICI therapy, even with positive tumor response.
  • Defining the spectrum of irAEs is crucial for personalized ICI treatment decisions.

Purpose of the Study:

  • To determine the incidence, risk factors, and clinical characteristics of ICI-induced diabetes, a severe irAE.
  • To investigate the association between genetic predisposition and the risk of developing ICI-induced diabetes.

Main Methods:

  • A cohort study of 14,328 adult patients treated with ICIs between July 2010 and January 2022.
  • Manual confirmation of ICI-induced diabetes cases, with detailed clinical phenotyping at diagnosis and 1-year follow-up.
  • Genotyping and calculation of polygenic risk scores for type 1 diabetes (T1D GRS2) in 862 patients.

Main Results:

  • The prevalence of ICI-induced diabetes was 0.45% (64/14,328 patients).
  • Significant risk factors included preexisting type 2 diabetes (OR, 5.91) and combination ICI therapy (OR, 2.57).
  • Higher T1D GRS2 was associated with increased ICI-induced diabetes risk (OR, 4.4), indicating a genetic link between autoimmunity and irAEs.

Conclusions:

  • ICI-induced diabetes is a significant irAE with identifiable clinical and genetic risk factors.
  • Patients with ICI-induced diabetes present with distinct phenotypes.
  • Understanding these factors can improve the diagnosis and management of ICI-induced diabetes and other irAEs as ICI use expands.